Enterprise Bank & Trust Co Has $244,000 Stock Position in Bristol-Myers Squibb (NYSE:BMY)

Enterprise Bank & Trust Co lifted its position in Bristol-Myers Squibb (NYSE:BMY) by 5.3% in the fourth quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The fund owned 4,321 shares of the biopharmaceutical company’s stock after buying an additional 217 shares during the quarter. Enterprise Bank & Trust Co’s holdings in Bristol-Myers Squibb were worth $244,000 as of its most recent filing with the Securities and Exchange Commission.

A number of other institutional investors and hedge funds have also modified their holdings of BMY. Cooper Financial Group raised its stake in Bristol-Myers Squibb by 2.0% during the 4th quarter. Cooper Financial Group now owns 14,152 shares of the biopharmaceutical company’s stock valued at $800,000 after purchasing an additional 279 shares during the last quarter. Wedmont Private Capital raised its stake in Bristol-Myers Squibb by 29.5% during the 4th quarter. Wedmont Private Capital now owns 10,487 shares of the biopharmaceutical company’s stock valued at $586,000 after purchasing an additional 2,392 shares during the last quarter. Talbot Financial LLC raised its stake in Bristol-Myers Squibb by 6.2% during the 4th quarter. Talbot Financial LLC now owns 99,996 shares of the biopharmaceutical company’s stock valued at $5,656,000 after purchasing an additional 5,813 shares during the last quarter. CHICAGO TRUST Co NA raised its stake in Bristol-Myers Squibb by 17.3% during the 4th quarter. CHICAGO TRUST Co NA now owns 22,204 shares of the biopharmaceutical company’s stock valued at $1,256,000 after purchasing an additional 3,270 shares during the last quarter. Finally, Brookstone Capital Management raised its stake in shares of Bristol-Myers Squibb by 11.0% in the 4th quarter. Brookstone Capital Management now owns 186,155 shares of the biopharmaceutical company’s stock valued at $10,529,000 after buying an additional 18,516 shares in the last quarter. 76.41% of the stock is currently owned by institutional investors and hedge funds.

Insider Transactions at Bristol-Myers Squibb

In related news, SVP Phil M. Holzer sold 700 shares of the business’s stock in a transaction on Monday, November 4th. The shares were sold at an average price of $55.62, for a total transaction of $38,934.00. Following the transaction, the senior vice president now directly owns 11,760 shares in the company, valued at approximately $654,091.20. The trade was a 5.62 % decrease in their ownership of the stock. The sale was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, EVP Samit Hirawat acquired 1,830 shares of the firm’s stock in a transaction on Friday, November 1st. The stock was bought at an average price of $54.67 per share, for a total transaction of $100,046.10. Following the completion of the acquisition, the executive vice president now owns 62,109 shares of the company’s stock, valued at approximately $3,395,499.03. The trade was a 3.04 % increase in their ownership of the stock. The disclosure for this purchase can be found here. 0.09% of the stock is currently owned by insiders.

Analyst Ratings Changes

A number of equities analysts have recently issued reports on BMY shares. Bank of America restated a “neutral” rating and issued a $63.00 price objective on shares of Bristol-Myers Squibb in a research note on Tuesday, December 10th. Truist Financial upped their target price on shares of Bristol-Myers Squibb from $62.00 to $65.00 and gave the stock a “buy” rating in a report on Wednesday, January 8th. Daiwa America upgraded shares of Bristol-Myers Squibb from a “hold” rating to a “strong-buy” rating in a research report on Wednesday, November 13th. Citigroup raised their price objective on shares of Bristol-Myers Squibb from $55.00 to $60.00 and gave the company a “neutral” rating in a research report on Tuesday, November 12th. Finally, Daiwa Capital Markets upgraded shares of Bristol-Myers Squibb from a “neutral” rating to an “outperform” rating in a research report on Wednesday, November 13th. Two analysts have rated the stock with a sell rating, thirteen have assigned a hold rating, four have given a buy rating and three have given a strong buy rating to the company. According to data from MarketBeat.com, Bristol-Myers Squibb has an average rating of “Hold” and a consensus target price of $56.27.

Bristol-Myers Squibb Stock Down 0.8 %

BMY traded down $0.46 during trading on Monday, reaching $55.37. The company had a trading volume of 4,328,995 shares, compared to its average volume of 9,244,007. The company has a debt-to-equity ratio of 2.83, a current ratio of 1.24 and a quick ratio of 1.09. Bristol-Myers Squibb has a 12 month low of $39.35 and a 12 month high of $61.08. The business’s fifty day moving average price is $57.44 and its 200 day moving average price is $51.56. The company has a market cap of $112.30 billion, a P/E ratio of -15.42, a PEG ratio of 15.20 and a beta of 0.45.

Bristol-Myers Squibb (NYSE:BMY) last announced its quarterly earnings data on Thursday, October 31st. The biopharmaceutical company reported $1.80 EPS for the quarter, topping analysts’ consensus estimates of $1.49 by $0.31. The business had revenue of $11.89 billion for the quarter, compared to analyst estimates of $11.26 billion. Bristol-Myers Squibb had a negative net margin of 15.30% and a positive return on equity of 11.94%. The firm’s revenue for the quarter was up 8.4% on a year-over-year basis. During the same quarter in the previous year, the firm posted $2.00 earnings per share. Equities analysts anticipate that Bristol-Myers Squibb will post 0.93 EPS for the current year.

Bristol-Myers Squibb Increases Dividend

The firm also recently disclosed a quarterly dividend, which will be paid on Monday, February 3rd. Stockholders of record on Friday, January 3rd will be given a $0.62 dividend. This represents a $2.48 dividend on an annualized basis and a dividend yield of 4.48%. The ex-dividend date of this dividend is Friday, January 3rd. This is a positive change from Bristol-Myers Squibb’s previous quarterly dividend of $0.60. Bristol-Myers Squibb’s payout ratio is currently -69.08%.

Bristol-Myers Squibb Profile

Bristol-Myers Squibb Company discovers, develops, licenses, manufactures, markets, distributes, and sells biopharmaceutical products worldwide. It offers products for hematology, oncology, cardiovascular, immunology, fibrotic, and neuroscience diseases. The company's products include Eliquis for reduction in risk of stroke/systemic embolism in non-valvular atrial fibrillation, and for the treatment of DVT/PE; Opdivo for various anti-cancer indications, including bladder, blood, CRC, head and neck, RCC, HCC, lung, melanoma, MPM, stomach and esophageal cancer; Pomalyst/Imnovid for multiple myeloma; Orencia for active rheumatoid arthritis and psoriatic arthritis; and Sprycel for the treatment of Philadelphia chromosome-positive chronic myeloid leukemia.